UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 140.49M | 109.79M | 96.52M | 94.24M | 91.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 140.49M | 109.79M | 96.52M | 94.24M | 91.87M |
| Cost of Revenue | 14.26M | 12.45M | 11.63M | 10.80M | 9.48M |
| Gross Profit | 126.24M | 97.34M | 84.89M | 83.43M | 82.39M |
| SG&A Expenses | 171.62M | 155.10M | 185.46M | 176.82M | 163.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 248.71M | 234.65M | 282.15M | 270.03M | 252.05M |
| Operating Income | -108.21M | -124.86M | -161.06M | -151.22M | -135.61M |
| Income Before Tax | -138.31M | -153.42M | -161.64M | -150.82M | -135.26M |
| Income Tax Expenses | -5.09M | 78.00K | 3.00M | 4.15M | 3.17M |
| Earnings from Continuing Operations | -133.23 | -153.49 | -164.64 | -154.97 | -138.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -133.23M | -153.49M | -164.64M | -154.97M | -138.43M |
| EBIT | -108.21M | -124.86M | -161.06M | -151.22M | -135.61M |
| EBITDA | -107.00M | -123.65M | -159.80M | -150.87M | -135.27M |
| EPS Basic | -2.75 | -3.20 | -3.46 | -3.27 | -3.05 |
| Normalized Basic EPS | -1.78 | -2.00 | -2.59 | -2.45 | -2.33 |
| EPS Diluted | -2.75 | -3.20 | -3.46 | -3.27 | -3.05 |
| Normalized Diluted EPS | -1.78 | -2.00 | -2.59 | -2.45 | -2.33 |
| Average Basic Shares Outstanding | 195.21M | 192.45M | 190.25M | 188.97M | 181.73M |
| Average Diluted Shares Outstanding | 195.21M | 192.45M | 190.25M | 188.97M | 181.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |